Rapport Therapeutics welcomes Terry-Ann Burrell to its Board of Directors

– USA, MA –  Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins to advance precision neuro medicines, today announced the appointment of Terry-Ann Burrell to its Board of Directors.

“We are very pleased to welcome Ms. Burrell to our board. With an exceptional track record of executive financial leadership and multi-billion-dollar financings in the biotech and pharma sectors, Ms. Burrell is an ideal addition. As we continue our journey to establish the leading precision neuroscience company, expanding our board with Ms. Burrell will undoubtedly propel our efforts to achieve our mission,” said CEO Abraham Ceesay.

About Terry-Ann Burrell

Ms. Burrell currently serves as CFO of Beam Therapeutics. Before Beam Therapeutics, Ms. Burrell was with J.P. Morgan for over a decade, most recently serving as Managing Director in the healthcare investment banking group. There, covering the biotechnology and pharmaceutical sectors, Ms. Burrell helped to execute over $10 billion in equity and equity-linked financings and more than $50 billion in M&A transactions. Before J.P. Morgan, Ms. Burrell worked in equity research at Citigroup, where she covered specialty pharmaceuticals and generics. Ms. Burrell holds an MBA from New York University Leonard N. Stern School of Business and a B.A. from Harvard University.

“This is an important moment for Rapport as the company prepares for both important clinical milestones and the complexities of the biotech financial landscape,” said Terry-Ann Burrell. “Rapport is poised for success and I look forward to leveraging my considerable experience working with early stage biotech companies to support this team as it charts new territory in neuromedicine.”

About Rapport Therapeutics

Rapport Therapeutics is developing a new class of precision neuro medicines that could give patients better alternatives to current treatments for neurological and psychiatric diseases, which often come with reduced efficacy and side effects that lead to suboptimal dosing, noncompliance, and discontinuation. By more precisely targeting the neural circuits and cell types where diseases originate, Rapport’s approach has the potential to reduce the unwanted drug-target interactions that lead to these issues. The company’s platform, built and refined over the past decade by its founding scientific team, achieves precision through the discovery and targeting of receptor-associated proteins, or RAPs, which display regional or neural circuit-specific expression. Rapport has ongoing clinical trials and discovery-stage programs in epilepsy, hearing, pain, and psychiatric disorders.

SOURCE: https://www.rapportrx.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.